Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Extended dosing of monoclonal antibodies in multiple sclerosis | Synapse

December 24, 2021Open Access

Ver artículo completo

Extended dosing of monoclonal antibodies in multiple sclerosis

ZKZoé LE van KempenAmsterdam Neuroscience ATAlyssa A TooropAmsterdam Neuroscience FSFinn SellebjergStatens Serum Institut

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

-integrin treatment (natalizumab) and anti-CD20 treatment (ocrelizumab, rituximab, and ofatumumab) in MS. In this review, current available evidence regarding personalized and extended interval dosing of monoclonal antibodies in MS is discussed with recommendations for future research and clinical practice.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Kempen et al. (Fri,) studied this question.

synapsesocial.com/papers/69fe0b6354949f8cfd5d52d5 https://doi.org/https://doi.org/10.1177/13524585211065711

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo